LihuaElizabethBuddeMDPhD

Oncology • Duarte, CA

Hematologic Oncology

Associate Professor, Dept. Of Hematology & HCT, City of Hope

Join to view full profile

Dr. Budde is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Budde's full profile

Already have an account?

Office
Division of Lymphoma
1500 East Duarte Road
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-389-3058

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2006 - 2009
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
Duke UniversityPh.D., 1995 - 2001
Tongji Medical UniversityClass of 1995

Certifications & Licensure

CA State Medical License 2012 - 2026
WA State Medical License 2006 - 2013

Awards, Honors, & Recognition

Clinical investigator Damon runyon cancer research foundation

Clinical Trials

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Start of enrollment: 2007 Dec 01
Completed
Phase 1, Phase 2
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Start of enrollment: 2015 Dec 15
Active, not recruiting
Phase 1
A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma Start of enrollment: 2016 Feb 01
Terminated
Phase 1
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2019 Aug 02
Recruiting
Phase 1, Phase 2
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Start of enrollment: 2020 Dec 31
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma.
Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, Charles Gaulin, Evandro Bezerra
American Journal of Hematology. 2024-12-23
Impact of prior CAR-T cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.
Elise A Chong, Elicia Penuel, Ellen B Napier, Rachel K Lundberg, Lihua Elizabeth Budde
Blood Advances. 2024-11-21
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
John A Thompson, Bryan J Schneider, Julie Brahmer, Mohammad Abu Zaid, Amaka Achufusi
Journal of the National Comprehensive Cancer Network. 2024-11-01

Abstracts/Posters

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cel...
Lihua E Budde, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Press Mentions

City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
Rituximab Key to Survival After Transplant for Mantle Cell LymphomaNovember 16th, 2017
$Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell Lymphoma$
Mosunetuzumab plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed or Refractory Aggressive Large B Cell LymphomaDecember 23rd, 2023
Join now to see all